Extended follow-up safety and effectiveness of the Endeavor zotarolimus-eluting stent in real-world clinical practice: Two-year follow-up from the E-Five Registry
Corresponding Author
Ian Meredith MBBS, PhD
MonashHeart, Monash Medical Centre and University, Melbourne, Australia
Monash Medical Centre and Monash University, 246 Clayton Road, Clayton, Melbourne, AustraliaSearch for more papers by this authorMartin Rothman MB, ChB
Barts and The London National Health Service Trust, London, United Kingdom
Conflict of interest: Ian T. Meredith, MBBS, PhD, has served as an advisory board member for Boston Scientific and Medtronic, Inc.; Martin T. Rothman, MB, ChB, has served as a consultant to Abbott Vascular, Cordis Corporation, JenaValve Technology GmbH, Lombard Medical Technologies PLC, Medtronic, Inc., and Volcano Corporation, has received research/grant support from Abbott Vascular, Boston Scientific, CardioBridge GmbH, Cordis Corporation, and Medtronic, Inc, and since this article was submitted has become an employee of Medtronic CardioVascular; Andrejs Erglis, PhD, has served as a consultant to Boston Scientific and Cordis Corporation; Chaim Lotan, MD, has served as a consultant for Angio Score Ltd. and Medtronic, Inc.
Search for more papers by this authorAndrejs Erglis MD, PhD
Pauls Stradins Clinical University Hospital, Riga, Latvia
Conflict of interest: Ian T. Meredith, MBBS, PhD, has served as an advisory board member for Boston Scientific and Medtronic, Inc.; Martin T. Rothman, MB, ChB, has served as a consultant to Abbott Vascular, Cordis Corporation, JenaValve Technology GmbH, Lombard Medical Technologies PLC, Medtronic, Inc., and Volcano Corporation, has received research/grant support from Abbott Vascular, Boston Scientific, CardioBridge GmbH, Cordis Corporation, and Medtronic, Inc, and since this article was submitted has become an employee of Medtronic CardioVascular; Andrejs Erglis, PhD, has served as a consultant to Boston Scientific and Cordis Corporation; Chaim Lotan, MD, has served as a consultant for Angio Score Ltd. and Medtronic, Inc.
Search for more papers by this authorKeyur Parikh MD
The Heart Clinic, Ahmedabad, India
Conflict of interest: Ian T. Meredith, MBBS, PhD, has served as an advisory board member for Boston Scientific and Medtronic, Inc.; Martin T. Rothman, MB, ChB, has served as a consultant to Abbott Vascular, Cordis Corporation, JenaValve Technology GmbH, Lombard Medical Technologies PLC, Medtronic, Inc., and Volcano Corporation, has received research/grant support from Abbott Vascular, Boston Scientific, CardioBridge GmbH, Cordis Corporation, and Medtronic, Inc, and since this article was submitted has become an employee of Medtronic CardioVascular; Andrejs Erglis, PhD, has served as a consultant to Boston Scientific and Cordis Corporation; Chaim Lotan, MD, has served as a consultant for Angio Score Ltd. and Medtronic, Inc.
Search for more papers by this authorChaim Lotan MD
Heart Institute, Hadassah-Hebrew University Medical Center, Jerusalem, Israel
Conflict of interest: Ian T. Meredith, MBBS, PhD, has served as an advisory board member for Boston Scientific and Medtronic, Inc.; Martin T. Rothman, MB, ChB, has served as a consultant to Abbott Vascular, Cordis Corporation, JenaValve Technology GmbH, Lombard Medical Technologies PLC, Medtronic, Inc., and Volcano Corporation, has received research/grant support from Abbott Vascular, Boston Scientific, CardioBridge GmbH, Cordis Corporation, and Medtronic, Inc, and since this article was submitted has become an employee of Medtronic CardioVascular; Andrejs Erglis, PhD, has served as a consultant to Boston Scientific and Cordis Corporation; Chaim Lotan, MD, has served as a consultant for Angio Score Ltd. and Medtronic, Inc.
Search for more papers by this authorfor the E-Five Investigators
A complete list of the E-Five Investigators is provided in the Appendix.
Conflict of interest: Ian T. Meredith, MBBS, PhD, has served as an advisory board member for Boston Scientific and Medtronic, Inc.; Martin T. Rothman, MB, ChB, has served as a consultant to Abbott Vascular, Cordis Corporation, JenaValve Technology GmbH, Lombard Medical Technologies PLC, Medtronic, Inc., and Volcano Corporation, has received research/grant support from Abbott Vascular, Boston Scientific, CardioBridge GmbH, Cordis Corporation, and Medtronic, Inc, and since this article was submitted has become an employee of Medtronic CardioVascular; Andrejs Erglis, PhD, has served as a consultant to Boston Scientific and Cordis Corporation; Chaim Lotan, MD, has served as a consultant for Angio Score Ltd. and Medtronic, Inc.
Search for more papers by this authorCorresponding Author
Ian Meredith MBBS, PhD
MonashHeart, Monash Medical Centre and University, Melbourne, Australia
Monash Medical Centre and Monash University, 246 Clayton Road, Clayton, Melbourne, AustraliaSearch for more papers by this authorMartin Rothman MB, ChB
Barts and The London National Health Service Trust, London, United Kingdom
Conflict of interest: Ian T. Meredith, MBBS, PhD, has served as an advisory board member for Boston Scientific and Medtronic, Inc.; Martin T. Rothman, MB, ChB, has served as a consultant to Abbott Vascular, Cordis Corporation, JenaValve Technology GmbH, Lombard Medical Technologies PLC, Medtronic, Inc., and Volcano Corporation, has received research/grant support from Abbott Vascular, Boston Scientific, CardioBridge GmbH, Cordis Corporation, and Medtronic, Inc, and since this article was submitted has become an employee of Medtronic CardioVascular; Andrejs Erglis, PhD, has served as a consultant to Boston Scientific and Cordis Corporation; Chaim Lotan, MD, has served as a consultant for Angio Score Ltd. and Medtronic, Inc.
Search for more papers by this authorAndrejs Erglis MD, PhD
Pauls Stradins Clinical University Hospital, Riga, Latvia
Conflict of interest: Ian T. Meredith, MBBS, PhD, has served as an advisory board member for Boston Scientific and Medtronic, Inc.; Martin T. Rothman, MB, ChB, has served as a consultant to Abbott Vascular, Cordis Corporation, JenaValve Technology GmbH, Lombard Medical Technologies PLC, Medtronic, Inc., and Volcano Corporation, has received research/grant support from Abbott Vascular, Boston Scientific, CardioBridge GmbH, Cordis Corporation, and Medtronic, Inc, and since this article was submitted has become an employee of Medtronic CardioVascular; Andrejs Erglis, PhD, has served as a consultant to Boston Scientific and Cordis Corporation; Chaim Lotan, MD, has served as a consultant for Angio Score Ltd. and Medtronic, Inc.
Search for more papers by this authorKeyur Parikh MD
The Heart Clinic, Ahmedabad, India
Conflict of interest: Ian T. Meredith, MBBS, PhD, has served as an advisory board member for Boston Scientific and Medtronic, Inc.; Martin T. Rothman, MB, ChB, has served as a consultant to Abbott Vascular, Cordis Corporation, JenaValve Technology GmbH, Lombard Medical Technologies PLC, Medtronic, Inc., and Volcano Corporation, has received research/grant support from Abbott Vascular, Boston Scientific, CardioBridge GmbH, Cordis Corporation, and Medtronic, Inc, and since this article was submitted has become an employee of Medtronic CardioVascular; Andrejs Erglis, PhD, has served as a consultant to Boston Scientific and Cordis Corporation; Chaim Lotan, MD, has served as a consultant for Angio Score Ltd. and Medtronic, Inc.
Search for more papers by this authorChaim Lotan MD
Heart Institute, Hadassah-Hebrew University Medical Center, Jerusalem, Israel
Conflict of interest: Ian T. Meredith, MBBS, PhD, has served as an advisory board member for Boston Scientific and Medtronic, Inc.; Martin T. Rothman, MB, ChB, has served as a consultant to Abbott Vascular, Cordis Corporation, JenaValve Technology GmbH, Lombard Medical Technologies PLC, Medtronic, Inc., and Volcano Corporation, has received research/grant support from Abbott Vascular, Boston Scientific, CardioBridge GmbH, Cordis Corporation, and Medtronic, Inc, and since this article was submitted has become an employee of Medtronic CardioVascular; Andrejs Erglis, PhD, has served as a consultant to Boston Scientific and Cordis Corporation; Chaim Lotan, MD, has served as a consultant for Angio Score Ltd. and Medtronic, Inc.
Search for more papers by this authorfor the E-Five Investigators
A complete list of the E-Five Investigators is provided in the Appendix.
Conflict of interest: Ian T. Meredith, MBBS, PhD, has served as an advisory board member for Boston Scientific and Medtronic, Inc.; Martin T. Rothman, MB, ChB, has served as a consultant to Abbott Vascular, Cordis Corporation, JenaValve Technology GmbH, Lombard Medical Technologies PLC, Medtronic, Inc., and Volcano Corporation, has received research/grant support from Abbott Vascular, Boston Scientific, CardioBridge GmbH, Cordis Corporation, and Medtronic, Inc, and since this article was submitted has become an employee of Medtronic CardioVascular; Andrejs Erglis, PhD, has served as a consultant to Boston Scientific and Cordis Corporation; Chaim Lotan, MD, has served as a consultant for Angio Score Ltd. and Medtronic, Inc.
Search for more papers by this authorA complete list of the E-Five Investigators is provided in the Appendix.
Abstract
Objectives: To present data from the cohort of patients in the all-comers Endeavor zotarolimus-eluting stent (ZES) registry (E-Five) who underwent 2-year follow-up. Background: The Endeavor ZES has been shown to be safe and efficacious for treatment of single, de novo lesions in patients with stable coronary artery disease. E-Five evaluated the ZES in over 8,000 real-world patients, at 188 sites followed to 1 year. A subset of sites continued follow-up through 2 years to evaluate late-term safety and effectiveness of the ZES in this population with diverse clinical and lesion characteristics. Methods: E-Five, a prospective, multicenter, nonrandomized global registry, collected 2-year outcomes for 2,116 patients from 26 centers. Sites were selected for participation based on patient accrual rates and the ability to continue follow-up activities for an additional year. Complete data was available for 2,054 patients. To observe whether or not a sustained benefit was achieved, data for all patients from the selected sites were included in the analysis. Results: The outcomes in the 2-year cohort tracked with the results of randomized controlled trials using the Endeavor ZES. One year results were MACE 7.5%, TLR 4.5%, and ARC definite/probable stent thrombosis 0.6%. Outcomes at 2 years for MACE, TLR, and ARC definite/probable stent thrombosis were 8.5, 5.1, and 0.7%, respectively. Conclusions: Long-term efficacy and safety outcomes were maintained between 1 and 2 years for the 2-year patient cohort, with only a small number of additional MACE, TLR, and very late stent thrombosis events. © 2010 Wiley-Liss, Inc.
REFERENCES
- 1 Kastrati A, Mehilli J, Pache J, et al. Analysis of 14 trials comparing sirolimus-eluting stents with bare-metal stents. N Engl J Med 2007; 356: 1030–1039.
- 2 Stone GW, Moses JW, Ellis SG, et al. Safety and efficacy of sirolimus- and paclitaxel-eluting coronary stents. N Engl J Med 2007; 356: 998–1008.
- 3 Fajadet J, Wijns W, Laarman GJ, et al. Randomized, double-blind, multicenter study of the Endeavor zotarolimus-eluting phosphorylcholine-encapsulated stent for treatment of native coronary artery lesions: Clinical and angiographic results of the ENDEAVOR II trial. Circulation 2006; 114: 798–806.
- 4 Jeremias A, Kirtane A. Balancing efficacy and safety of drug-eluting stents in patients undergoing percutaneous coronary intervention. Ann Intern Med 2008; 148: 234–238.
- 5 Urban P, Gershlick AH, Guagliumi G, et al. Safety of coronary sirolimus-eluting stents in daily clinical practice: One-year follow-up of the e-Cypher registry. Circulation 2006; 113: 1434–1441.
- 6 Simonton CA, Brodie B, Cheek B, et al. Comparative clinical outcomes of paclitaxel and sirolimus-eluting stents: Results from a large prospective multicenter registry–STENT group. J Am Coll Cardiol 2007; 50: 1214–1222.
- 7 Lasala JM, Cox DA, Dobies D, et al. Usage patterns and 2-year outcomes with the TAXUS express stent: Results of the ARRIVE 1 Registry. Catheter Cardiovasc Interv 2008; 72: 433–445.
- 8 Lotan C, Meredith IT, Mauri L, Liu M, Rothman MT for the E-Five Investigators. Safety and efficacy of the Endeavor zotarolimus-eluting stent in real-world clinical practice: 12-month data from the E-Five Registry. J Am Coll Cardiol Interv 2009; 2: 1227–1235.
- 9 Cutlip DE, Windecker S, Mehran R, et al. Academic research consortium. Clinical endpoints in coronary stent trials: A case for standardized definitions. Circulation 2007; 115: 2344–2351.
- 10 Dou KF, Xu B, Yang YJ, et al. Two-year clinical outcome after successful implantation of drug-eluting and bare metal stents in diabetic patients: Results from a real-world, single center registry. Chin Med J 2009; 122: 612–616.
- 11 Lasala JM, Cox DA, Lewis SJ, et al. Expanded use of the TAXUS express stent: Two-year safety insights from the 7,500 patient ARRIVE Registry programme. EuroIntervention 2009; 5: 67–77.
- 12 Marzocchi A, Saia F, Piovaccari G, et al. Long-term safety and efficacy of drug eluting stents: Two-year results of the REAL (Registro Angiop Lastiche dell'Emilia Romagna) multicenter registry. Circulation 2007; 115: 3181–3188.
- 13 Tu JV, Bowen J, Chui M, et al. Effectiveness and safety of drug-eluting stents in Ontario. N Engl J Med 2007; 357: 1393–1402.
- 14 Byrne RA, Kufner S, Tiroch K, et al. Randomized trial of three rapamycin-eluting stents with different coating strategies for the reduction of coronary restenosis: 2-year follow-up results. Heart 2009; 95: 1489–1494.
- 15 Kandzari DE, Leon MB, Popma JJ, et al. Comparison of zotarolimus-eluting and sirolimus-eluting stents in patients with native coronary artery disease: A randomized controlled trial. J Am Coll Cardiol 2006; 48: 2440–2447.
- 16 Gershlick A, Kandzari DE, Leon MB, et al. Zotarolimus-eluting stents in patients with native coronary artery disease: Clinical and angiographic outcomes in 1,317 patients. Am J Cardiol 2007; 100 ( Suppl): 45M–55M.
- 17 Lee CH, Low AF, Hong EC, et al. Long-term safety and efficacy are observed after implantation of zotarolimus-eluting stent in real-world clinical practice. EuroIntervention 2008; 4: 338–344.
- 18 Leon MB, Mauri L, Popma JJ, et al. A randomized comparison of the ENDEAVOR zotarolimus-eluting stent versus the TAXUS paclitaxel-eluting stent in de novo native coronary lesions: 12-month outcomes from the ENDEAVOR IV trial. J Am Coll Cardiol 2010; 55: 543–554.
- 19 Grines CL, Bonow RO, Casey DE, et al. Prevention of premature discontinuation of dual antiplatelet therapy in patients with coronary artery stents. A science advisory from the American Heart Association, American College of Cardiology, Society for Cardiovascular Angiography and Interventions, American College of Surgeons, and American Dental Association with representation from the American College of Physicians. J Am Coll Cardiol 2007; 49: 734–739.
- 20 Kandzari DE, Angiolillo DJ, Price MJ, Teirstein PS. Identifying the “optimal” duration of dual antiplatelet therapy after drug eluting stent revascularization. J Am Coll Cardiol Interv 2009; 2: 1279–1285.
